e-learning
resources
ERJ
2016
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The adrenergic nervous system as a therapeutic target in pulmonary arterial hypertension: a cautionary tale
Rubin Lewis J.
Source:
Eur Respir J 2016; 48: 617-618
Journal Issue:
September
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Rubin Lewis J.. The adrenergic nervous system as a therapeutic target in pulmonary arterial hypertension: a cautionary tale. Eur Respir J 2016; 48: 617-618
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertension
Source: Eur Respir J 2009; 34: 792-794
Year: 2009
Clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertension
Source: Eur Respir J 2010; 35: 704-705
Year: 2010
Novel therapeutic perspectives in pulmonary arterial hypertension
Source: Eur Respir J 2003; 22: 193-194
Year: 2003
Parasympathetic activity in pulmonary arterial hypertension: could a simple measure do the trick?
Source: International Congress 2018 – Pulmonary hypertension: right ventricle function, haemodynamics and exercise
Year: 2018
Challenging the concept of adding more drugs in pulmonary arterial hypertension
Source: Eur Respir J, 50 (3) 1701527; 10.1183/13993003.01527-2017
Year: 2017
Targeting HIF2a-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension
Source: Eur Respir J, 57 (3) 1902061; 10.1183/13993003.02061-2019
Year: 2021
Beta 3 adrenoceptor: a potential therapeutic target for pulmonary arterial hypertension
Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Year: 2020
Renin-angiotensin-aldosterone system activation in different vasculature areas in primary pulmonary hypertension
Source: Eur Respir J 2004; 24: Suppl. 48, 1s
Year: 2004
Leptin signalling system as a target for pulmonary arterial hypertension therapy
Source: Eur Respir J 2015; 45: 1066-1080
Year: 2015
The dopaminergic system in pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II
Year: 2013
Sympathetic nervous system activation is an independent prognostic factor of clinical deterioration in pulmonary arterial hypertensive patients
Source: Annual Congress 2009 - Pulmonary arterial hypertension
Year: 2009
Pulmonary arterial hypertension or left heart disease with pulmonary hypertension? Toward noninvasive clarity, but time for a new paradigm
Source: Eur Respir J 2015; 46: 299-302
Year: 2015
Novel treatment for pulmonary vascular disease: lessons from pathophysiology
Source: Annual Congress 2006 - Molecular pathology: an approach to lung diseases
Year: 2006
Exercise intolerance in pulmonary arterial hypertension: insight into central and peripheral pathophysiological mechanisms
Source: Eur Respir Rev, 30 (160) 200284; 10.1183/16000617.0284-2020
Year: 2021
Hepatotoxicity complicating treatment of pulmonary and central nervous system tuberculosis
Source: Eur Respir J 2002; 20: Suppl. 38, 548s
Year: 2002
Goal-oriented therapy in paediatric pulmonary arterial hypertension: are we ready?
Source: Eur Respir J 2014; 44: 1404-1407
Year: 2014
Acute vasodilator testing in idiopathic pulmonary arterial hypertension: must we take NO for the answer?
Source: Eur Respir J 2009; 33: 1247-1249
Year: 2009
Is there an obesity paradox in pulmonary arterial hypertension?
Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Year: 2017
The revolution of pulmonary arterial hypertension
Source: Eur Respir Rev 2016; 25: 361-363
Year: 2016
Autoimmunity and pulmonary arterial hypertension: The role of leptin
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept